U.K.-based LumiraDx has developed a COVID-19 antigen test in use by the U.K.’s NHS and CVS Health in the U.S.
April 07, 2021 at 02:57 PM
1 minute read
The original version of this story was published on American Lawyer
CA Healthcare Acquisition Corp. (CACH), a SPAC looking to invest in growth-oriented companies in the health care industry, found what it was looking for in London-headquartered LumiraDx Limited. The two entities have reached a definitive merger agreement that will list LumiraDx on Nasdaq under “LMDX” and gives the company a valuation of $5 billion.
Fried, Frank, Harris, Shriver & Jacobson and Goodwin Procter represented LumiraDx in the transaction, while Sidley Austin represented the SPAC.
Presented by BigVoodoo
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
The African Legal Awards recognise exceptional achievement within Africa s legal community during a period of rapid change.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
People wait in line to be tested for COVID-19 at the Convention Center in downtown Baltimore, on Nov. 13, 2020. Photo: Diego M. Radzinschi/ALM
